Business Context and Reporting Period
This Form 8-K is filed by Oculus Innovative Sciences, Inc. (not Sonoma Pharmaceuticals, Inc.) on March 6, 2012. The report addresses a regulatory matter regarding the company's listing status on the NASDAQ Capital Market.
Key Financial Metrics
The filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric referenced is the Market Value of Listed Securities, which must be maintained at a minimum of $35 million to comply with NASDAQ Listing Rule 5550(b)(2).
Material Changes
- Previous Status: On February 7, 2012, the company received notice of non-compliance with NASDAQ rules due to failing to maintain the $35 million market value requirement for 30 consecutive business days.
- Current Status: On March 6, 2012, the company received confirmation that it has regained compliance by maintaining the required market value for the last 10 consecutive business days.
- Resolution: The listing deficiency matter is now resolved.
Guidance, Outlook, and Risks
The filing contains standard forward-looking statements regarding intentions, beliefs, and expectations. Management notes that actual outcomes may differ materially due to risks and uncertainties discussed in the Annual Report on Form 10-K. No specific operational guidance or new risk factors were introduced in this report.
Investor Verification Checklist
- Verify the current market capitalization to ensure continued compliance with the $35 million threshold.
- Review the most recent Form 10-K for detailed financial performance and risk factors.
- Confirm the company's ticker symbol and listing status on the NASDAQ Capital Market.